Another key factor is weight loss itself
When evaluating the effects of treatment if all people adhered to treatment from a mean baseline body weight of 113kg, people treated with semaglutide 7.2mg achieved a superior weight loss of 20.7% after 72 weeks compared to a reduction of 17.5% with semaglutide 2.4mg and 2.4% with placebo
Regular follow-up with your primary care provider allows assessment of weight trends, metabolic parameters (lipids, glucose, blood pressure), and obesity-related comorbidities
Medical and Pharmacological Options Metformin Metformin is an insulin-sensitising medication originally developed for type 2 diabetes, which is now being widely used in PCOS management
Furthermore, increased CRP levels explained part of the elevated risk of COVID-19related mortality with age, specifically in the absence of obesity and impaired metabolic health